Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PePS2: Pembrolizumab in PS2 NSCLC
NCT02733159Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Jan 2017
- Primary completion
- Feb 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by University of Birmingham. Started Jan 2017; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02733159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02733159.